Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antirheumatic Agents | 10 | 2021 | 3023 | 1.81 | Why? |
| Arthritis, Rheumatoid | 7 | 2021 | 2043 | 1.14 | Why? |
| Rheumatic Diseases | 6 | 2021 | 2675 | 0.77 | Why? |
| Spondylitis, Ankylosing | 2 | 2018 | 231 | 0.72 | Why? |
| Adiponectin | 1 | 2018 | 123 | 0.67 | Why? |
| Antibodies, Antinuclear | 4 | 2019 | 234 | 0.66 | Why? |
| Rituximab | 2 | 2021 | 1096 | 0.63 | Why? |
| Biosimilar Pharmaceuticals | 1 | 2019 | 205 | 0.62 | Why? |
| Autoimmune Diseases | 5 | 2021 | 1996 | 0.57 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2018 | 2483 | 0.51 | Why? |
| Clodronic Acid | 1 | 2011 | 10 | 0.48 | Why? |
| Bone Density Conservation Agents | 1 | 2011 | 209 | 0.38 | Why? |
| Osteoarthritis | 1 | 2011 | 205 | 0.37 | Why? |
| T-Lymphocytes | 2 | 2021 | 6670 | 0.28 | Why? |
| Cytokines | 4 | 2020 | 15010 | 0.27 | Why? |
| Etanercept | 3 | 2019 | 162 | 0.26 | Why? |
| Fluorescent Antibody Technique, Indirect | 3 | 2019 | 393 | 0.25 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.24 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.23 | Why? |
| Synovitis, Pigmented Villonodular | 1 | 2020 | 2 | 0.22 | Why? |
| Giant Cell Tumor of Tendon Sheath | 1 | 2020 | 3 | 0.22 | Why? |
| Treatment Failure | 3 | 2018 | 2106 | 0.21 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.20 | Why? |
| Lymphocyte Depletion | 1 | 2021 | 293 | 0.20 | Why? |
| Vaccination | 6 | 2021 | 19050 | 0.19 | Why? |
| Lymphocyte Count | 3 | 2021 | 4758 | 0.19 | Why? |
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 502 | 0.18 | Why? |
| Immunity, Cellular | 2 | 2021 | 3614 | 0.18 | Why? |
| Luminescent Measurements | 2 | 2020 | 924 | 0.18 | Why? |
| Immunologic Surveillance | 1 | 2018 | 69 | 0.17 | Why? |
| Spondylarthritis | 1 | 2020 | 174 | 0.17 | Why? |
| Myositis | 2 | 2018 | 185 | 0.17 | Why? |
| Transcription Factors | 2 | 2019 | 784 | 0.16 | Why? |
| Glucuronidase | 1 | 2017 | 103 | 0.16 | Why? |
| Arthritis | 2 | 2018 | 288 | 0.16 | Why? |
| Immune System Diseases | 1 | 2021 | 410 | 0.16 | Why? |
| Cytoplasm | 1 | 2018 | 304 | 0.16 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 245 | 0.16 | Why? |
| Connective Tissue Diseases | 1 | 2017 | 187 | 0.15 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.14 | Why? |
| Costs and Cost Analysis | 1 | 2019 | 694 | 0.14 | Why? |
| Interferon-gamma | 2 | 2021 | 2711 | 0.14 | Why? |
| Complement Activation | 1 | 2020 | 949 | 0.13 | Why? |
| Immune Tolerance | 1 | 2018 | 608 | 0.12 | Why? |
| Biological Products | 2 | 2018 | 2331 | 0.12 | Why? |
| Chemokines | 1 | 2018 | 1095 | 0.12 | Why? |
| Hand Joints | 1 | 2011 | 31 | 0.12 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.12 | Why? |
| Hyperalgesia | 1 | 2011 | 61 | 0.11 | Why? |
| Humans | 33 | 2021 | 930598 | 0.11 | Why? |
| Prisons | 1 | 2021 | 980 | 0.11 | Why? |
| Autoantibodies | 2 | 2019 | 2094 | 0.11 | Why? |
| Scleroderma, Systemic | 1 | 2017 | 583 | 0.11 | Why? |
| Arthritis, Psoriatic | 1 | 2017 | 625 | 0.11 | Why? |
| Hand Strength | 1 | 2011 | 202 | 0.10 | Why? |
| Lung Diseases, Interstitial | 2 | 2018 | 1476 | 0.10 | Why? |
| B-Lymphocytes | 2 | 2021 | 4418 | 0.10 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.10 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.09 | Why? |
| Immunoglobulin M | 3 | 2020 | 9091 | 0.09 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.09 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.09 | Why? |
| Pain Measurement | 1 | 2011 | 533 | 0.09 | Why? |
| Hydroxychloroquine | 1 | 2011 | 12447 | 0.08 | Why? |
| Immunoassay | 2 | 2020 | 4485 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.08 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.08 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.08 | Why? |
| Autoantigens | 2 | 2019 | 388 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.07 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.07 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.07 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.06 | Why? |
| Adalimumab | 2 | 2018 | 389 | 0.06 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.06 | Why? |
| Pain | 1 | 2011 | 1084 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Immunoglobulin G | 3 | 2020 | 21571 | 0.06 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.06 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.05 | Why? |
| Pilot Projects | 1 | 2011 | 5182 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| United Kingdom | 1 | 2019 | 18046 | 0.05 | Why? |
| Ligases | 1 | 2018 | 36 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Knee Joint | 1 | 2020 | 194 | 0.05 | Why? |
| Certolizumab Pegol | 1 | 2018 | 36 | 0.04 | Why? |
| Glomerulonephritis | 1 | 2021 | 226 | 0.04 | Why? |
| Uveitis | 1 | 2021 | 233 | 0.04 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.04 | Why? |
| Fibromyalgia | 1 | 2020 | 174 | 0.04 | Why? |
| Immunoblotting | 1 | 2018 | 180 | 0.04 | Why? |
| Health Status | 1 | 2011 | 3259 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| Expert Testimony | 1 | 2021 | 658 | 0.04 | Why? |
| Aged | 6 | 2021 | 215776 | 0.04 | Why? |
| Retreatment | 1 | 2017 | 186 | 0.04 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.03 | Why? |
| Italy | 4 | 2021 | 38444 | 0.03 | Why? |
| Biological Factors | 1 | 2018 | 276 | 0.03 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Infliximab | 1 | 2018 | 502 | 0.03 | Why? |
| Syndrome | 1 | 2018 | 1310 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Adult | 5 | 2021 | 244371 | 0.03 | Why? |
| Opportunistic Infections | 1 | 2018 | 602 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.02 | Why? |
| Male | 7 | 2021 | 367725 | 0.02 | Why? |
| Mexico | 1 | 2017 | 2787 | 0.02 | Why? |
| Female | 7 | 2021 | 380317 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Lung Diseases | 1 | 2021 | 2361 | 0.02 | Why? |
| Workflow | 1 | 2017 | 2373 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.02 | Why? |
| Skin Diseases | 1 | 2021 | 2509 | 0.02 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.02 | Why? |
| Biomarkers | 2 | 2017 | 23361 | 0.02 | Why? |
| Inflammatory Bowel Diseases | 1 | 2021 | 3209 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Cell Line | 1 | 2019 | 12040 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Young Adult | 1 | 2021 | 93724 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |
Benucci's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(152)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(99)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_